Boothbay Fund Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Boothbay Fund Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-277,311	Closed	-$68.5K	–	2591
2026 Q1	$68.5K	Hold	277,311	–	–	﹤0.01%	1903
2025 Q4	$116K	Sell	277,311 -75,981	-22%	-$40.3K	﹤0.01%	1726
2025 Q3	$238K	Buy	353,292 +34,473	+11%	+$18.6K	﹤0.01%	1572
2025 Q2	$173K	Sell	318,819 -218,400	-41%	-$130K	﹤0.01%	1268
2025 Q1	$352K	Hold	537,219	–	–	0.01%	990
2024 Q4	$548K	Buy	+537,219	New	+$982K	0.01%	835
2020 Q2	–	Sell	-11,100	Closed	-$71K	–	1095
2020 Q1	$71K	Buy	+11,100	New	+$82.4K	0.01%	765
2018 Q3	–	Sell	-25,600	Closed	-$364K	–	931
2018 Q2	$364K	Buy	+25,600	New	+$425K	0.03%	419

Other funds holding SGMO

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

AIM

Axiom Investment Management New York $150M AUM

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

Boothbay Fund Management's SGMO Position: Q2 2026 in Review

Boothbay Fund Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 277,311 shares — an estimated $68.5K sold.

Boothbay Fund Management first reported a position in SGMO in Q2 2018 and held it in 8 quarters. The position peaked at $548K in Q4 2024. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

Boothbay Fund Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 277,311 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $68.5K.
Boothbay Fund Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2018 and held it in 8 quarters.
Boothbay Fund Management's SANGAMO THERAPEUTICS INC position peaked at $548K in Q4 2024.
6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.